Welgene Biotech Co.Ltd.
Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables… Read more
Welgene Biotech Co.Ltd. (6661) - Net Assets
Latest net assets as of September 2025: NT$293.46 Million TWD
Based on the latest financial reports, Welgene Biotech Co.Ltd. (6661) has net assets worth NT$293.46 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$554.58 Million) and total liabilities (NT$261.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$293.46 Million |
| % of Total Assets | 52.92% |
| Annual Growth Rate | 9.98% |
| 5-Year Change | 17.01% |
| 10-Year Change | 48.09% |
| Growth Volatility | 22.24 |
Welgene Biotech Co.Ltd. - Net Assets Trend (2014–2024)
This chart illustrates how Welgene Biotech Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Welgene Biotech Co.Ltd. (2014–2024)
The table below shows the annual net assets of Welgene Biotech Co.Ltd. from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$295.75 Million | -1.51% |
| 2023-12-31 | NT$300.27 Million | -1.21% |
| 2022-12-31 | NT$303.95 Million | -1.97% |
| 2021-12-31 | NT$310.06 Million | +22.68% |
| 2020-12-31 | NT$252.74 Million | +0.79% |
| 2019-12-31 | NT$250.75 Million | +1.70% |
| 2018-12-31 | NT$246.55 Million | +10.25% |
| 2017-12-31 | NT$223.63 Million | +9.76% |
| 2016-12-31 | NT$203.73 Million | +2.02% |
| 2015-12-31 | NT$199.71 Million | +74.77% |
| 2014-12-31 | NT$114.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Welgene Biotech Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4211100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$290.24 Million | 100.81% |
| Total Equity | NT$287.91 Million | 100.00% |
Welgene Biotech Co.Ltd. Competitors by Market Cap
The table below lists competitors of Welgene Biotech Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gibb River Diamonds Limited
F:PHO
|
$3.31 Million |
|
Goodyear Indonesia Tbk
JK:GDYR
|
$3.31 Million |
|
Hochdorf Holding AG
SW:HOCN
|
$3.31 Million |
|
Visa Steel Limited
NSE:VISASTEEL
|
$3.31 Million |
|
Sadbhav Infrastructure Project Limited
NSE:SADBHIN
|
$3.31 Million |
|
EXCELLENCE S.A. ZY -10
F:8XY
|
$3.30 Million |
|
ASIA-PACIFIC STR.INV.LTD.
F:2HN
|
$3.30 Million |
|
Original Juice Co. Ltd.
AU:OJC
|
$3.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Welgene Biotech Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 292,034,000 to 287,911,000, a change of -4,123,000 (-1.4%).
- Net income of 1,107,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 11,565,999.
- Other factors increased equity by 6,335,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$1.11 Million | +0.38% |
| Other Comprehensive Income | NT$-11.57 Million | -4.02% |
| Other Changes | NT$6.34 Million | +2.2% |
| Total Change | NT$- | -1.41% |
Book Value vs Market Value Analysis
This analysis compares Welgene Biotech Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.52x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.80x to 1.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | NT$10.41 | NT$18.75 | x |
| 2015-12-31 | NT$12.42 | NT$18.75 | x |
| 2016-12-31 | NT$9.81 | NT$18.75 | x |
| 2017-12-31 | NT$10.75 | NT$18.75 | x |
| 2018-12-31 | NT$11.84 | NT$18.75 | x |
| 2019-12-31 | NT$12.03 | NT$18.75 | x |
| 2020-12-31 | NT$12.13 | NT$18.75 | x |
| 2021-12-31 | NT$13.41 | NT$18.75 | x |
| 2022-12-31 | NT$13.02 | NT$18.75 | x |
| 2023-12-31 | NT$12.53 | NT$18.75 | x |
| 2024-12-31 | NT$12.35 | NT$18.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Welgene Biotech Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.34%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.83x
- Recent ROE (0.38%) is below the historical average (7.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 18.50% | 7.81% | 1.21x | 1.95x | NT$9.69 Million |
| 2015 | 10.67% | 7.68% | 0.99x | 1.41x | NT$1.34 Million |
| 2016 | 2.01% | 1.47% | 1.01x | 1.36x | NT$-16.26 Million |
| 2017 | 10.59% | 7.26% | 1.04x | 1.40x | NT$1.31 Million |
| 2018 | 11.51% | 7.37% | 1.06x | 1.47x | NT$3.71 Million |
| 2019 | 12.32% | 7.39% | 0.99x | 1.69x | NT$5.82 Million |
| 2020 | 11.79% | 7.48% | 1.10x | 1.43x | NT$4.52 Million |
| 2021 | 4.42% | 4.38% | 0.74x | 1.37x | NT$-17.28 Million |
| 2022 | 3.14% | 2.97% | 0.74x | 1.43x | NT$-20.82 Million |
| 2023 | -0.91% | -0.94% | 0.51x | 1.88x | NT$-31.85 Million |
| 2024 | 0.38% | 0.34% | 0.61x | 1.83x | NT$-27.68 Million |
Industry Comparison
This section compares Welgene Biotech Co.Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $528,316,000
- Average return on equity (ROE) among peers: -0.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Welgene Biotech Co.Ltd. (6661) | NT$293.46 Million | 18.50% | 0.89x | $3.31 Million |
| Bionet (1784) | $1.32 Billion | 2.02% | 0.36x | $107.18 Million |
| DIVA Laboratories Ltd (4153) | $1.02 Billion | 4.89% | 0.23x | $25.67 Million |
| Kim Forest Enterprise Co., Ltd. (6645) | $32.49 Million | 0.00% | 7.10x | $20.40 Million |
| Puriblood Medical Co., Ltd. (6847) | $175.40 Million | -3.06% | 0.48x | $13.28 Million |
| TFBS Bioscience Inc. (6939) | $247.95 Million | 0.12% | 0.16x | $5.40K |
| Pharmigene, Inc. (7595) | $382.22 Million | -6.13% | 0.10x | $10.10 Million |